Skip to main content
Exercise of warrants brings in $5.74M for OncoCyte

OncoCyte secured $5.74 million after certain warrant holders exercised around 1.77 million common stock purchase warrants. The proceeds will be used to develop the company's liquid biopsy diagnostics for breast and lung cancer as well as to prepare for this year's release of its lung cancer diagnostic, said company President and CEO William Annet.

Full Story: